New painkiller aims to replace opioids after skin cancer surgery
NCT ID NCT07575230
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares a new non-opioid drug, suzetrigine, to the standard opioid painkiller hydrocodone/acetaminophen for pain after Mohs skin cancer surgery. Researchers want to see if suzetrigine can control pain just as well while reducing the need for opioids. The trial involves 75 adults aged 18-89 who are having Mohs surgery for skin tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Suzetrigine
- What this could lead to
- If successful, suzetrigine could offer a non-opioid option for managing pain after skin cancer surgery, reducing reliance on opioids.
- What could go wrong
- This is a small, early-phase trial with only 75 participants. The drug may not control pain as well as standard care, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Baylor University Medical Center
Dallas, Texas, 75246, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.